• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间质性肺疾病:急性加重的预后影响的回顾性研究

Interstitial lung disease: retrospective study of the prognostic impact of acute exacerbations.

作者信息

Pacheco Joana, Santos Ana Isabel, Catarata Maria Joana, Freitas Sara

机构信息

Hospital and University Centre of Coimbra.

Braga Hospital.

出版信息

Sarcoidosis Vasc Diffuse Lung Dis. 2024 Dec 10;41(4):e2024051. doi: 10.36141/svdld.v41i4.15198.

DOI:10.36141/svdld.v41i4.15198
PMID:39655596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11708956/
Abstract

BACKGROUND

Interstitial lung diseases have high mortality associated with hospitalization for decompensation. There are doubts about the factors involved in the progression of fibrosis, for example the role played by acute exacerbations.  With this work, the authors intend to analyze whether there are predictive parameters of mortality related to exacerbations.

METHODS

A retrospective study was carried out of patients admitted to the Pulmonology department of Coimbra University Hospital Center for exacerbation of fibrosing lung disease between January 2019 and December 2020. These were classified as: idiopathic pulmonary fibrosis (IPF), fibrosing hypersensivity pneumonitis (FHP) and other fibrosing lung diseases. Statistical analysis was performed using SPSS 26.0 considering statistically significant p<0.05 values.

RESULTS

The results show that IPF is associated with longer hospital stay in relation to fibrosing HP and other fibrosing lung diseases mean of 20.93 days (95% CI: 14.69-27.18) vs 11.8 days (95% CI: 1.05-17.22, p=0.023) vs 12.23 days (95% CI 2.06-15.34, p=0.007), respectively. Regarding mortality, there was no difference between IPF, PH and other fibrosing diseases (p=0.631).

CONCLUSION

This study demonstrated that IPF, compared to PH and other fibrosing diseases, is associated with longer hospital stays, probably due to its progressive course despite the institution of corticosteroid therapy. As shown in previous studies, it was concluded that there is no difference in terms of mortality between IPF exacerbations and other forms of fibrosing lung disease.

摘要

背景

间质性肺疾病因失代偿住院而死亡率较高。对于纤维化进展所涉及的因素存在疑问,例如急性加重所起的作用。通过这项研究,作者旨在分析是否存在与加重相关的死亡预测参数。

方法

对2019年1月至2020年12月间因纤维化性肺病加重而入住科英布拉大学医院中心肺病科的患者进行了一项回顾性研究。这些患者被分类为:特发性肺纤维化(IPF)、纤维化性过敏性肺炎(FHP)和其他纤维化性肺病。使用SPSS 26.0进行统计分析,考虑p<0.05的统计学显著值。

结果

结果显示,与纤维化性HP和其他纤维化性肺病相比,IPF的住院时间更长,平均分别为20.93天(95%CI:14.69 - 27.18)、11.8天(95%CI:1.05 - 17.22;p = 0.023)和12.23天(95%CI:2.06 - 15.34;p = 0.007)。关于死亡率,IPF、PH和其他纤维化疾病之间没有差异(p = 0.631)。

结论

本研究表明,与PH和其他纤维化疾病相比,IPF的住院时间更长,可能是由于其尽管采用了皮质类固醇治疗但仍呈进行性病程。如先前研究所示,得出的结论是IPF加重与其他形式的纤维化性肺病在死亡率方面没有差异。

相似文献

1
Interstitial lung disease: retrospective study of the prognostic impact of acute exacerbations.间质性肺疾病:急性加重的预后影响的回顾性研究
Sarcoidosis Vasc Diffuse Lung Dis. 2024 Dec 10;41(4):e2024051. doi: 10.36141/svdld.v41i4.15198.
2
Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.特发性肺纤维化患者住院和恶化的模式及经济负担。
J Manag Care Spec Pharm. 2016 Apr;22(4):414-23. doi: 10.18553/jmcp.2016.22.4.414.
3
Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study.与结缔组织疾病相关的纤维性间质性肺疾病的急性加重:一项基于人群的研究。
BMC Pulm Med. 2019 Nov 14;19(1):215. doi: 10.1186/s12890-019-0960-1.
4
Burden of illness in progressive fibrosing interstitial lung disease.进展性肺纤维化间质性肺疾病的疾病负担。
J Manag Care Spec Pharm. 2022 Aug;28(8):871-880. doi: 10.18553/jmcp.2022.28.8.871.
5
Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.美国非特发性肺纤维化纤维化性间质性肺疾病患者疾病进展的基于索赔的患病率。
Ann Am Thorac Soc. 2022 Jul;19(7):1112-1121. doi: 10.1513/AnnalsATS.202102-222OC.
6
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.可能对进展性肺纤维化非特发性肺纤维化间质性肺疾病患者有抗纤维化药物的价值。
BMC Pulm Med. 2019 Nov 12;19(1):213. doi: 10.1186/s12890-019-0937-0.
7
Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.抗纤维化治疗对非特发性肺纤维化性肺纤维化性间质性肺疾病的疾病进展、全因死亡率和急性加重风险的影响:来自随机对照试验和前瞻性对照研究的荟萃分析证据。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241232561. doi: 10.1177/17534666241232561.
8
Differences between Acute Exacerbations of Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.特发性肺纤维化急性加重与其他间质性肺疾病之间的差异
Diagnostics (Basel). 2021 Sep 6;11(9):1623. doi: 10.3390/diagnostics11091623.
9
Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.韩国全国性纤维化性间质性肺病(F-ILD)的流行病学研究:一项基于人群的研究。
BMC Pulm Med. 2023 Mar 22;23(1):98. doi: 10.1186/s12890-023-02373-z.
10
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.基于美国保险索赔数据的非特发性肺纤维化进行性纤维化性间质性肺疾病患者的医疗资源利用和费用。
Adv Ther. 2020 Jul;37(7):3292-3298. doi: 10.1007/s12325-020-01380-4. Epub 2020 May 21.

本文引用的文献

1
Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases.特发性肺纤维化及其他间质性肺疾病急性加重住院患者的临床表现和预后因素分析。
BMJ Open Respir Res. 2024 Feb 27;11(1):e001997. doi: 10.1136/bmjresp-2023-001997.
2
Re-hospitalisation predicts poor prognosis after acute exacerbation of interstitial lung disease.再入院预示着间质性肺疾病急性加重后的不良预后。
BMC Pulm Med. 2023 Jul 1;23(1):236. doi: 10.1186/s12890-023-02534-0.
3
Differences between Acute Exacerbations of Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.特发性肺纤维化急性加重与其他间质性肺疾病之间的差异
Diagnostics (Basel). 2021 Sep 6;11(9):1623. doi: 10.3390/diagnostics11091623.
4
Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases.慢性间质性肺疾病急性加重的特征与评估。
Respir Med. 2021 Jul;183:106400. doi: 10.1016/j.rmed.2021.106400. Epub 2021 Apr 26.
5
Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?特发性肺纤维化急性加重:临床分层或类固醇治疗重要吗?
Chron Respir Dis. 2019 Jan-Dec;16:1479973119869334. doi: 10.1177/1479973119869334.
6
Treatment of acute exacerbations of interstitial lung disease.间质性肺疾病急性加重的治疗。
Expert Rev Respir Med. 2018 Apr;12(4):309-313. doi: 10.1080/17476348.2018.1446831. Epub 2018 Mar 12.
7
Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis.间质性肺疾病的急性加重:来自特发性肺纤维化的经验教训
Curr Opin Pulm Med. 2017 Sep;23(5):411-417. doi: 10.1097/MCP.0000000000000405.
8
Interstitial lung disease.间质性肺疾病。
Eur Respir Rev. 2014 Mar 1;23(131):40-54. doi: 10.1183/09059180.00009113.
9
Acute exacerbations of idiopathic pulmonary fibrosis.特发性肺纤维化的急性加重
Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43. doi: 10.1164/rccm.200703-463PP. Epub 2007 Jun 21.